BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced a collaboration with Kentucky Organ Donor Affiliates (KODA). KODA is an independent, non-profit organ and tissue procurement organization that facilitates deceased donor transplants throughout Kentucky, southern Indiana and western West Virginia. The collaboration will advance preclinical studies of the potential of Talaris allogeneic cell therapy to induce immune tolerance to an organ from a deceased donor.

Organ donation from deceased donors makes possible more than 80 percent of solid organ transplants in the U.S. These transplants are frequently lifesaving, but they bring the burden of lifelong immunosuppression for organ recipients, which puts patients at heightened risk of infection as well as a number of other potentially serious side effects. Additionally, immunosuppressant drugs are toxic to the kidneys over time, which can result in declining kidney function and necessitate another organ transplant.

Talaris novel cell therapy, FCR001, has shown promising potential to eliminate the need for immunosuppression among recipients of kidney transplants from living donors. Our collaboration with KODA will be an important step toward potentially extending this promise to recipients of organ transplants from deceased donors as well, said Scott Requadt, Chief Executive Officer of Talaris.

Within the collaboration, KODA, after authorization from the donors family, will recover vertebrae from deceased organ donors. Researchers at Talaris will then isolate stem cells from the vertebrae, with the goal of demonstrating the feasibility of producing FCR001 from vertebral bone marrow. These preclinical studies will serve as a first step toward enabling future clinical studies to evaluate whether FCR001 administered alongside organ transplantation can induce durable immune tolerance to an organ from a deceased donor.

The generosity organ donors and their families display is measureless. By initiating this collaboration with Talaris, we hope to further honor their gift by advancing an important treatment for transplant recipients with the potential to improve many individuals lives, said Julie Bergin, RN, BSN, MHA, President & Chief Executive Officer of KODA.

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Talaris was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville, KY. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA and maintains corporate offices in Boston, MA and Louisville, KY. http://www.TalarisTx.com.

About Kentucky Organ Donor Affiliates (KODA)

Kentucky Organ Donor Affiliates is dedicated to saving lives through organ and tissue donation and transplantation. KODA is an independent, federally designated, non-profit organ and tissue procurement organization formed in 1987. KODA was recognized by Louisville Business First as the Nonprofit of the Year in 2011. KODAs mission is to provide organ and tissues to those in need and to maintain a profound respect for those who gave. KODA serves 114 counties in Kentucky, 4 counties in southern Indiana and 2 counties in western West Virginia. For more information visit donatelifeky.org or call 1-800-525-3456.

Read the rest here:
Talaris Therapeutics Announces Collaboration With Kentucky Organ Donor Affiliates to Advance Preclinical Study of Tolerance Induction to Organs From...

Bone Marrow Stem Cells Comments Off on Talaris Therapeutics Announces Collaboration With Kentucky Organ Donor Affiliates to Advance Preclinical Study of Tolerance Induction to Organs From… | September 14th, 2020

Rosh Hashanah is the day of pregnancy of the world. Hayom Harat Olam (The day of creation of the world). What does it mean?Medical research today is focusing on a fascinating and visionary field, which is the study of "stem cells."The uniqueness of stem cells comes from two main features which distinguish them from other cells. The first is that they are still 'neutral cells', meaning, they have not yet received their final identity and purpose in the body, so they have not yet finalized their differentiation process. As a result of this, they are able to differentiate and can develop into one of many types of mature cells, such as a skin cell, a muscle cell or a blood cell. By doing so, new cells are created, which can regenerate various tissues and organs.The second unique feature of stem cells is that they are able to divide and multiply infinitely and produce identical cells. Thus, a constant pool of unsorted stem cells that have not acquired a final designation is preserved.The possibilities of healing, cell regeneration and the human body in general are fascinating, and the field of stem cells is one of the leading fields in the world. Its healing potentials are so vast, not only when it comes to repairing the damaged, but also recreating something more true and precise.When I think of Rosh Hashanah from a spiritual standpoint, it feels like today is the birth of the world. We have before us 353 days (because some Jewish months arent full) which have not yet been defined by how they will play out and how they will look. It is unknown how we will succeed as individuals, and how we will succeed as nation. Interestingly, the second feature that exists with stem cells also connects to Rosh Hashanah. On this holy day, we are praying and asking Hashem from a place of "anything is possible" there are no boundaries, no glass barriers, no one is stopping us from simply praying and asking. cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });Hashem, everything is completely in our hands! We can change the world and create something entirely new. Rosh Hashanah gives us the opportunity to create and build anew; its the source of rebirth for the relationship between man and his friend, man and Hashem, and of course, man as one who is part of a nation and of the entire world.It's not for nothing that it is written in the Talmud Yerushalmi that whoever spends his time on Rosh Hashanah sleeping, his luck will also sleep. It's the time to act, ask, beg and change.The cells will divide, the decisions made will be in place, and the abundance from shamayim (heaven) will come down. We now have a very great ability and opportunity to influence that. Please dont miss out on this opportunity!Be that as it may, today is Harat Olam the pregnancy of the world. It is our responsibility to pray that this pregnancy will be the best it can be. Have a happy and sweet New Year.Rabbi Yitzak Neriya is the head of the Torah Betzion yeshiva and founder of the Echad Lechad (One to One) foundation.

See the original post here:
Stem cells, like Rosh Hashanah, give the opportunity to be reborn - The Jerusalem Post

Skin Stem Cells Comments Off on Stem cells, like Rosh Hashanah, give the opportunity to be reborn – The Jerusalem Post | September 14th, 2020

Venus pokes Uranus, provoking your mother, sister or aunt to ruffle your feathers. Stand your ground and dont allow anyone to sway you from your purpose. Although well-intentioned, this person isnt fully informed, and most importantly,she isnt living your life. Theres no need for harsh words, just gently remind her thatyoure capable of making your own decisions. And thats that!

Although this week brings a breath of fresh air in the form of a new project or chapter, someone is intent on undermining you. Their doubts stem from jealousy, so dont allow them to project their negativity onto you. Stay your course, Pisces. Come up with your own facts rather than listening to biased opinions. Believe in yourself and toss the naysayers to the curb.

A self-confessed astrology nerd, Natashas horoscopes, research and articles have been published in Todays Astrologer, in addition to international publications across the globe. A senior member of the Australian Academy of Astrology and Cosmobiology and a member of the American Federation of Astrologers, she has presented cosmic updates for Your Life Naturally and has appeared as a special guest on podcasts, including Sivana and Healthy-ish.

Feature Image: Supplied.

Go here to see the original:
HOROSCOPES: How Thursday's new moon will affect your week, according to your star sign. - Mamamia

Skin Stem Cells Comments Off on HOROSCOPES: How Thursday’s new moon will affect your week, according to your star sign. – Mamamia | September 14th, 2020

Sherrie Hewson faced up to turning 70 this week by giving herself a real lift.

The Benidorm and Corrie star, who hits the milestone birthday on Thursday, has had a second facelift to boost her confidence after a really tough year that saw her beloved brother die and left her lonely in lockdown.

Sherrie says she was completely broken after her older sibling Brett Hutchinson passed away in April and she couldnt visit him because of coronavirus restrictions.

Brett died of a brain tumour and the shock of his death has left Sherrie more determined than ever to live life to the full.

She told the Sunday Mirror: I am still not very strong, I still have moments. Whenever I hear any Motown music, which he loved, I just cry. The pain is so terrible, my heart is broken.

Now I look at my life and think, Hang on a minute, what have I got, how long have I got?

I mean, look at my brother. Two years ago he was the healthiest thing on this planet.

So none of us know whats going to happen.

In ten years time I am going to be 80, so I need to be healthy and well for my grandchildren.

I wish I had planned more when I was younger. Instead I just went steaming ahead, thinking I was going to live forever.

Brett was only a couple of years older than me, so as I go into my seventies his death has made me want to live every day to the max.

I want to do everything now everything crazy, mad and wonderful. Everything that is possible to do I want to do it now.

And that all started with her facelift.

Dubbed the love handle facelift or LHF Sherries procedure took just minutes and she went out to lunch straight afterwards.

The procedure involved removing fat from around her hips and stomach. This was then combined with her blood, to release stem cells from the fat.

The mixture, a thick serum, was then injected into layers into her face without even drawing blood. The results will last five years.

Sherrie said: The LHF was a quick treatment and its given me such a boost. I feel like its rejuvenated my skin and restored all the volume its natural looking with no cutting, and it was all done in under an hour.

I absolutely love the results.

She adds: I had a facelift when I was 50 and Ive had bits and bobs done throughout the years a bit of botox and filler. But I havent had anything done for a long time now.

But as I approached 70. I just thought, What will I do for myself at this age? I thought I would give myself a last kind of boost so I can look in the mirror and think, Youre not bad for your age.

Its to give myself a lift after all the stuff I have been through, particularly in the last 18 months.

I need to give my self-confidence and self-worth a big kick up the a**e so can I feel good about myself and hold my head up high.

The actress , who lives alone, says she found lockdown awful and even turned to drinking wine every night to get through it.

She says: It was just terrifying being alone. Thank God for the internet! I have been doing the Wonderbirds show and Ive been presenting courses on Zoom. That kept my mind busy.

I did put on weight and I am trying to be more sensible now. I started drinking, and I was drinking every night which I would never do. Then I thought, I must stop this.

So I stopped for two months and I didnt even miss it. Thats when I realised I didnt have a problem. I was just bored and lonely.

Now Sherrie is hoping to spend the next decade healthy and happy and maybe even in love.

Her Corrie character Maureen Webster had four husbands, including Reg Holdsworth, played by Ken Morley. But Sherrie says she hasnt even had a proper date since her marriage to Ken Boyd broke down in 2001, after he had an affair.

Now she hopes her facelift will give her the boost she needs to start going out with people again.

She says: Dating is harder as you get older - the older you get, the more you lack confidence. I sometimes look in the mirror and dont know who that much older woman is.

Sherrie would be more than happy with a kiss and cuddle with someone with their arms around you.

She says: I cant imagine any more what that feels like that warmth and that someone who wants to be with me. Just that alone would be enough.

Sherrie, who played flirty hotel manager Joyce Temple-Savage in ITV sitcom Benidorm, says she has had a couple of potential love interests.

One was a younger American man she met on dating site Plenty of Fish. But they came to nothing.

She says: I havent really dated since I broke up with my husband except I did go for a meal with a man and I ordered a bottle of wine. He put the cork in the bottle and said he was driving and I said, Im bloody not! and took the cork out.

We got back to my house and he tried kissing me and I just thought, No!

But passion is still on Sherries wishlist as shes still open to an unbelievable affair with the right man.

She also has dreams of launching a travel programme for older people showing that they can still do crazy, mad and wonderful things.

Because coronavirus restrictions are set to change again tomorrow, with the new Rule of Six, Sherrie wont be able to celebrate her birthday as she had hoped with a big bash. But she will spend the day with daughter Keeley and youngest grand-daughter Rosie, who turned one in May.

Reflecting on her own age, the gran-of-three says: I have been on this earth for 70 years. Doesnt that sound weird?

The thing is how the hell did I get to number seven? When I got to number six I was gobsmacked. But you know what? A lot of people dont get to number seven, so how lucky am I?

Ive got a wonderful family and Ive had a fabulous career. My family are my life blood, I breathe for them.

And Im healthy, thank God. When you moan and groan about getting older and I do, all the time I tell myself my great grandmother, grandmother and my mum all lived until their eighties and nineties. So I am on a good wicket there arent I?

Sherrie admits she sometimes envies her daughters family life.

She says: Ive been on stage since I was four and, when I look back, my whole life has been my career.

I have no regrets, except that I would have had more children, given the chance. Keeley is at home with her three and I never had the privilege to do that. I was working so much.

But instead of dwelling on the past, Sherrie is determined to look ahead from now on. She says: At 70, I am still finding out who I am and what I want to do with my life.

Fat Transfer and Stromal Vascular fraction

We are increasingly using fat along with concentrated platelet rich plasma as a natural lipo filler to add volume where there has been for fat loss and to help with skin rejuvenation.

Fat is the bodys major source of mesenchymal stem cells, which are considered multi-potent, as they have the ability to differentiate themselves into a number of different types of stem cells that are useful for regeneration, tissue repair and wound healing. PRP is used to promote cell growth and collagen production, so is extremely useful for Creping and thinning skin.

Combined they make the perfect treatment to regenerate and rejuvenate and replace lost volume due to ageing.

What is it? An all-natural alternative incision free facelift

Downtime? 0-24 hours

How long does it last? Up to five years

Where can I get it? http://www.harleystreetskinclinic.com 0207 436 4441

How much is it? FROM 3,950

Follow this link:
Sherrie Hewson turns 70 with second facelift after tough year left her 'broken' - Mirror Online

Skin Stem Cells Comments Off on Sherrie Hewson turns 70 with second facelift after tough year left her ‘broken’ – Mirror Online | September 14th, 2020

Sept. 14, 2020 10:45 UTC

BOTHELL, Wash. & KENILWORTH, N.J.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005237/en/

The companies will globally develop and commercialize Seattle Genetics ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting LIV-1, which is currently in phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. Under the terms of the agreement, Seattle Genetics will receive a $600 million upfront payment and Merck will make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share. In addition, Seattle Genetics is eligible for progress-dependent milestone payments of up to $2.6 billion.

Separately, Seattle Genetics has granted Merck an exclusive license to commercialize TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Seattle Genetics will receive $125 million from Merck as an upfront payment and is eligible for progress-dependent milestones of up to $65 million.

Collaborating with Merck on ladiratuzumab vedotin will allow us to accelerate and broaden its development program in breast cancer and other solid tumors, including in combination with Mercks KEYTRUDA, while also positioning us to leverage our U.S. and European commercial operations, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. The strategic collaboration for TUKYSA will help us reach more patients globally and benefit from the established commercial strength of one of the worlds premier pharmaceutical companies.

These two strategic collaborations will enable us to further diversify Mercks broad oncology portfolio and pipeline, and to continue our efforts to extend and improve the lives of as many patients with cancer as possible, said Dr. Roger M. Perlmutter, President, Merck Research Laboratories. We look forward to working with the team at Seattle Genetics to advance the clinical program for ladiratuzumab vedotin, which has shown compelling signals of efficacy in early studies, and to bring TUKYSA to even more patients with cancer around the world.

Ladiratuzumab Vedotin Collaboration Details

Under the terms of the agreement, Seattle Genetics and Merck will collaborate and equally share costs on the global development of ladiratuzumab vedotin and other LIV-1-targeting ADCs. The companies have agreed to jointly develop and share future costs and profits for ladiratuzumab vedotin on a 50:50 basis worldwide. Merck will pay Seattle Genetics $600 million upfront and make a $1.0 billion equity investment in 5.0 million shares of Seattle Genetics common stock at a price of $200 per share. In addition, Seattle Genetics will be eligible to receive up to $2.6 billion in milestone payments, including $850 million in development milestones and $1.75 billion in sales milestones.

The companies will jointly develop and commercialize ladiratuzumab vedotin and equally share profits worldwide. The companies will co-commercialize in the U.S. and Europe. Seattle Genetics will be responsible for marketing applications for approval in the U.S. and Canada, and will record sales in the U.S., Canada and Europe. Merck will be responsible for marketing applications for approval in Europe and in countries outside the U.S. and Canada, and will record sales in countries outside the U.S., Europe and Canada. Including the upfront payment, equity investment proceeds and potential milestone payments, Seattle Genetics is eligible to receive up to $4.2 billion.

The closing of the equity investment is contingent on completion of review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).

TUKYSA Collaboration Details

Under the terms of the agreement, Merck has been granted exclusive rights to commercialize TUKYSA in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Seattle Genetics retains commercial rights and will record sales in the U.S., Canada and Europe. Merck will be responsible for marketing applications for approval in its territory, supported by the positive results from the HER2CLIMB clinical trial.

Merck will also co-fund a portion of the TUKYSA global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Seattle Genetics will continue to lead ongoing TUKYSA global development planning and operational execution. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territory.

Seattle Genetics will receive from Merck $125 million as an upfront payment and is eligible to receive progress-dependent milestones of up to $65 million. Seattle Genetics will also receive $85 million in prepaid research and development payments to be applied to Mercks global development funding obligations. In addition, Seattle Genetics would receive tiered royalties on sales of TUKYSA in Mercks territory.

The financial impact of these collaborations is not included in Seattle Genetics 2020 guidance.

Seattle Genetics Conference Call Details

Seattle Genetics management will host a conference call to discuss these collaborations today at 6:00 a.m. Pacific Time (PT); 9:00 a.m. Eastern Time (ET). The event will be simultaneously webcast and available for replay from the Seattle Genetics website at http://www.seattlegenetics.com, under the Investors section. Investors may also participate in the conference call by calling 844-763-8274 (domestic) or +1 412-717-9224 (international). The conference ID is 10147850.

About Ladiratuzumab Vedotin

Ladiratuzumab vedotin is a novel investigational ADC targeted to LIV-1. Most metastatic breast cancers express LIV-1, which also has been detected in several other cancers, including lung, head and neck, esophageal and gastric. Ladiratuzumab vedotin utilizes Seattle Genetics proprietary ADC technology and consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response by induction of immunogenic cell death.

About TUKYSA (tucatinib)

TUKYSA is an oral, small molecule tyrosine kinase inhibitor (TKI) of HER2, a protein that contributes to cancer cell growth. TUKYSA in combination with trastuzumab and capecitabine was approved by the U.S. Food and Drug Administration (FDA) in April 2020 for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. In addition, TUKYSA received approval in Canada, Singapore, Australia and Switzerland under the Project Orbis initiative of the FDA Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology products among international partners. A marketing application is under review in the European Union.

TUKYSA is being evaluated in several ongoing clinical trials and additional studies are planned. Current trials include the following:

For additional information, visit http://www.clinicaltrials.gov.

TUKYSA Important Safety Information

Warnings and Precautions

If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA.

Adverse Reactions

Serious adverse reactions occurred in 26% of patients who received TUKYSA. Serious adverse reactions in 2% of patients who received TUKYSA were diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). Fatal adverse reactions occurred in 2% of patients who received TUKYSA including sudden death, sepsis, dehydration, and cardiogenic shock.

Adverse reactions led to treatment discontinuation in 6% of patients who received TUKYSA; those occurring in 1% of patients were hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions led to dose reduction in 21% of patients who received TUKYSA; those occurring in 2% of patients were hepatotoxicity (8%) and diarrhea (6%).

The most common adverse reactions in patients who received TUKYSA (20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea, fatigue, hepatotoxicity, vomiting, stomatitis, decreased appetite, abdominal pain, headache, anemia, and rash.

Lab Abnormalities

In HER2CLIMB, Grade 3 laboratory abnormalities reported in 5% of patients who received TUKYSA were: decreased phosphate, increased ALT, decreased potassium, and increased AST. The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.

Drug Interactions

Use in Specific Populations

For more information, please see the full Prescribing Information for TUKYSA here.

About KEYTRUDA (pembrolizumab) Injection, 100 mg

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,200 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected KEYTRUDA (pembrolizumab) Indications

Melanoma

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Small Cell Lung Cancer

KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Head and Neck Squamous Cell Cancer

KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) 1] as determined by an FDA-approved test.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [combined positive score (CPS) 10], as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

KEYTRUDA is indicated for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Esophageal Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Hepatocellular Carcinoma

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merkel Cell Carcinoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Renal Cell Carcinoma

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Tumor Mutational Burden-High

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Selected Important Safety Information for KEYTRUDA

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65/790) of NSCLC patients receiving KEYTRUDA as a single agent, including Grades 3-4 in 3.2% of patients, and occurred more frequently in patients with a history of prior thoracic radiation (17%) compared to those without (7.7%). Pneumonitis occurred in 6% (18/300) of HNSCC patients receiving KEYTRUDA as a single agent, including Grades 3-5 in 1.6% of patients, and occurred in 5.4% (15/276) of patients receiving KEYTRUDA in combination with platinum and FU as first-line therapy for advanced disease, including Grades 3-5 in 1.5% of patients.

Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (<0.1%). Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.

Immune-Mediated Hepatitis (KEYTRUDA) and Hepatotoxicity (KEYTRUDA in Combination With Axitinib)

Immune-Mediated Hepatitis

KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.4%), and 4 (<0.1%). Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.

Hepatotoxicity in Combination With Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity with higher than expected frequencies of Grades 3 and 4 ALT and AST elevations compared to KEYTRUDA alone. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased ALT (20%) and increased AST (13%) were seen. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed.

Immune-Mediated Endocrinopathies

KEYTRUDA can cause adrenal insufficiency (primary and secondary), hypophysitis, thyroid disorders, and type 1 diabetes mellitus. Adrenal insufficiency occurred in 0.8% (22/2799) of patients, including Grade 2 (0.3%), 3 (0.3%), and 4 (<0.1%). Hypophysitis occurred in 0.6% (17/2799) of patients, including Grade 2 (0.2%), 3 (0.3%), and 4 (<0.1%). Hypothyroidism occurred in 8.5% (237/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC (16%) receiving KEYTRUDA, as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. Hyperthyroidism occurred in 3.4% (96/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and thyroiditis occurred in 0.6% (16/2799) of patients, including Grade 2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 0.2% (6/2799) of patients.

Monitor patients for signs and symptoms of adrenal insufficiency, hypophysitis (including hypopituitarism), thyroid function (prior to and periodically during treatment), and hyperglycemia. For adrenal insufficiency or hypophysitis, administer corticosteroids and hormone replacement as clinically indicated. Withhold KEYTRUDA for Grade 2 adrenal insufficiency or hypophysitis and withhold or discontinue KEYTRUDA for Grade 3 or Grade 4 adrenal insufficiency or hypophysitis. Administer hormone replacement for hypothyroidism and manage hyperthyroidism with thionamides and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and withhold KEYTRUDA and administer antihyperglycemics in patients with severe hyperglycemia.

Immune-Mediated Nephritis and Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.1%), and 4 (<0.1%) nephritis. Nephritis occurred in 1.7% (7/405) of patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue for Grade 3 or 4 nephritis.

Read more:
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations - BioSpace

Cardiac Stem Cells Comments Off on Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations – BioSpace | September 14th, 2020

Sept. 14, 2020 12:00 UTC

BOSTON & BORDENTOWN, N.J.--(BUSINESS WIRE)-- Alexion Pharmaceuticals Inc.. (NASDAQ:ALXN) and Caelum Biosciences, Inc. today announced the initiation of the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101, a first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in AL amyloidosis. The CARES clinical program includes two parallel Phase 3 studies one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease and will collectively enroll approximately 370 patients globally. Enrollment is underway in both studies. The primary objective of the clinical program is to assess overall survival.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005234/en/

In AL amyloidosis, misfolded amyloid proteins can build up in many organs throughout the body, including the heart and kidneys, causing significant damage to these organs and impairing their function. While current treatments address the bone marrow disorder that creates the misfolded amyloid proteins, there are no approved therapies for the significant organ damage the disease causes, said John Orloff, M.D., Executive Vice President and Head of Research and Development at Alexion. CAEL-101 has the potential to be the first treatment to target and remove the amyloid deposits from these organs. Data from Phase 1 studies suggest that this treatment approach may improve organ function and long-term survival. We look forward to investigating this further in the Phase 3 clinical program.

AL amyloidosis is particularly devastating when it affects the heart, with median survival in these patients of less than one year following diagnosis, said Michael Spector, President and Chief Executive Officer of Caelum. Long-term survival data from AL amyloidosis patients treated with CAEL-101 in the Phase 1a/1b study showed that 78 percent were still alive after a median follow-up time of more than three years. We recognize the urgent need for new treatments that address the organ damage caused by AL amyloidosis and are working together with the AL amyloidosis community and Alexion to advance the Phase 3 clinical program as quickly as possible.

About the CARES Phase 3 Clinical Program

The CARES clinical program consists of two parallel double-blind, randomized, event-driven global Phase 3 studies, which are evaluating the efficacy and safety of CAEL-101 in AL amyloidosis patients who are newly diagnosed and nave to standard of care (SoC) treatment (cyclophosphamide-bortezomib-dexamethasone (CyBorD) chemotherapy). One study is enrolling approximately 260 patients with Mayo stage IIIa disease and one study is enrolling approximately 110 patients with Mayo stage IIIb disease. The studies will be conducted at approximately 70 sites across North America, the United Kingdom, Europe, Israel, Japan, and Australia.

In each study, participants are being randomized in a 2:1 ratio to receive either CAEL-101 plus SoC or placebo plus SoC once weekly for four weeks. This will be followed by a maintenance dose administered every two weeks until the last patient enrolled completes at least 50 weeks of treatment. Patients will continue follow-up visits every 12 weeks.

The primary study objectives are overall survival and the safety and tolerability of CAEL-101. Key secondary objectives will assess functional improvement in the six-minute walk test (6MWT), quality of life measures (Kansas City Cardiomyopathy Questionnaire Overall Score & Short Form 36 version 2 Physical Component Score) and cardiac improvement (Global Longitudinal Strain, or GLS).

Phase 2 Study Results

The Phase 2 open-label dose escalation study was conducted to investigate higher doses of CAEL-101 than had been evaluated in Phase 1 studies with a primary objective to identify the best dose to advance into Phase 3 development. The study evaluated the safety and tolerability of CAEL-101 in 13 AL amyloidosis patients at three study sites who received up to 1000 mg/m2 of CAEL-101 (two times the Phase 1 dose) administered in combination with SoC treatment. The study met its primary objectives, supporting the safety and tolerability of CAEL-101 and the selection of the 1000 mg/m2 dose for the Phase 3 study.

Phase 1a/1b Long-Term Follow-Up Results Presented at ISA 2020

As previously reported, the Phase 1a/1b study of CAEL-101 was the first clinical trial to demonstrate improvement in cardiac function via GLS after treatment with an amyloid fibril targeted therapy in AL amyloidosis patients with amyloid cardiac involvement. New long-term follow-up data from the Phase 1a/1b study will be presented at the virtual International Symposium on Amyloidosis (ISA), September 14 to 18, 2020, in the poster titled, Long term follow-up of patients with AL amyloidosis treated on a phase 1 study of Anti-Amyloid Monoclonal Antibody CAEL-101 (Abstract #342, Divaya Bhutani, M.D., et. al, Columbia University Medical Center). These data demonstrate 78 percent survival (15/19) at a median follow-up of more than three years (37 months) in AL amyloidosis patients treated with CAEL-101 as well as durable organ response among evaluable patients, further supporting the advancement of CAEL-101 into Phase 3 development.

About CAEL-101

CAEL-101 is a first-in-class monoclonal antibody (mAb) designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis. The antibody is designed to bind to misfolded light chain protein and amyloid and shows binding to both kappa and lambda subtypes. In a Phase 1a/1b study, CAEL-101 demonstrated improved organ function, including cardiac and renal function, in 27 patients with relapsed and refractory AL amyloidosis who had previously not had an organ response to standard of care therapy. CAEL-101 has received Orphan Drug Designation from both the U.S. Food and Drug Administration and European Medicine Agency as a therapy for patients with AL amyloidosis.

About AL Amyloidosis

AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. Misfolded immunoglobulin light chains produced by plasma cells aggregate and form fibrils that deposit in tissues and organs. This deposition can cause widespread and progressive organ damage and high mortality rates, with death most frequently occurring as a result of cardiac failure. Current standard of care includes plasma cell directed chemotherapy and autologous stem cell transplant, but these therapies do not address the organ dysfunction caused by amyloid deposition, and up to 80 percent of patients are ineligible for transplant.

AL amyloidosis is a rare disease but is the most common form of amyloidosis. There are approximately 22,000 patients across the United States, France, Germany, Italy, Spain and the United Kingdom. AL amyloidosis has a one-year mortality rate of 47 percent, 76 percent of which is caused by cardiac amyloidosis.

About Alexion

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: http://www.alexion.com.

[ALXN-P]

About Caelum Biosciences

Caelum Biosciences, Inc. (Caelum) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Caelums lead asset, CAEL-101, is a novel antibody for the treatment of patients with amyloid light chain (AL) amyloidosis. In 2019, Caelum entered a collaboration agreement with Alexion under which Alexion acquired a minority equity interest in Caelum and an exclusive option to acquire the remaining equity in the company based on Phase 3 CAEL-101 data. Caelum was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit http://www.caelumbio.com.

Forward-Looking Statement

This press release contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Alexion and Caelum, including statements related to: the safety and efficacy CAEL-101 as a treatment for AL amyloidosis; CAEL-101 has the potential to be the first treatment to target and remove the amyloid deposits from the heart, kidney and other organs; data from the Phase 1 studies suggest that the treatment approach may improve organ function and long-term survival and enrollment of the Phase 3 trials. Forward-looking statements are subject to factors that may cause Alexion's and Caelums results and plans to differ materially from those expected by these forward looking statements, including for example: the anticipated safety profile and the benefits of the CAEL-101 may not be realized (and the results of the clinical trials may not be indicative of future results); the inability to enroll and complete the Phase 3 trial; results of clinical trials may not be sufficient to satisfy regulatory authorities; results in clinical trials may not be indicative of results from later stage or larger clinical trials (or in broader patient populations); the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to discontinue sales of the product (or halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates); the severity of the impact of the COVID-19 pandemic on Alexions or Caelums business, including on commercial and clinical development programs; unexpected delays in clinical trials; unexpected concerns regarding products and product candidates that may arise from additional data or analysis obtained during clinical trials or obtained once used by patients following product approval; future product improvements may not be realized due to expense or feasibility or other factors; delays (expected or unexpected) in the time it takes regulatory agencies to review and make determinations on applications for the marketing approval of our products; inability to timely submit (or failure to submit) future applications for regulatory approval for our products and product candidates; inability to timely initiate (or failure to initiate) and complete future clinical trials due to safety issues, IRB decisions, CMC-related issues, expense or unfavorable results from earlier trials (among other reasons); future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by regulatory agencies regarding our products and product candidates; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us; the risk that third party payors (including governmental agencies) will not reimburse for the use of our products at acceptable rates or at all; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; adverse impacts on supply chain, clinical trials, manufacturing operations, financial results, liquidity, hospitals, pharmacies and health care systems from natural disasters and global pandemics, including COVID-19 and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended June 30, 2020 and in their other filings with the SEC. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005234/en/

See the original post here:
Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - BioSpace

Cardiac Stem Cells Comments Off on Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis – BioSpace | September 14th, 2020

Global Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Geography (North America, Europe, Asia-Pacific and Latin America)

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

To Remain Ahead Of Your Competitors, Request for a FREE Sample Here (with covid 19 Impact Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&DW

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

Make an Enquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&DW

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process.

The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Read More@ https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market?DW

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email @ Corporatesales@databridgemarketresearch.com

Original post:
Exosome Therapeutic Market (Covid 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 - Good...

Cardiac Stem Cells Comments Off on Exosome Therapeutic Market (Covid 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2027 – Good… | September 14th, 2020

The report is an all-inclusive research study of the global Hematopoietic Stem Cell Transplantation (HSCT) market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Hematopoietic Stem Cell Transplantation (HSCT) market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Hematopoietic Stem Cell Transplantation (HSCT) report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2773144&source=atm

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Hematopoietic Stem Cell Transplantation (HSCT) market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Hematopoietic Stem Cell Transplantation (HSCT) market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the Hematopoietic Stem Cell Transplantation (HSCT) report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

segment by Type, the product can be split intoAllogeneicAutologousMarket segment by Application, split intoPeripheral Blood Stem Cells Transplant (PBSCT)Bone Marrow Transplant (BMT)Cord Blood Transplant (CBT)

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2773144&source=atm

The Hematopoietic Stem Cell Transplantation (HSCT) report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Hematopoietic Stem Cell Transplantation (HSCT) market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Hematopoietic Stem Cell Transplantation (HSCT) market and its potential to grow in the years to come.

Highlights of the Report

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2773144&licType=S&source=atm

Table of Contents Covered in the Report:

1 Hematopoietic Stem Cell Transplantation (HSCT) Market Overview

1 Hematopoietic Stem Cell Transplantation (HSCT) Product Overview

1.2 Hematopoietic Stem Cell Transplantation (HSCT) Market Segment by Type

1.3 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size by Type

1.3.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales and Growth by Type

1.3.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales and Market Share by Type (2015-2020)

1.3.3 Global Hematopoietic Stem Cell Transplantation (HSCT) Revenue and Market Share by Type (2015-2020)

1.3.4 Global Hematopoietic Stem Cell Transplantation (HSCT) Price by Type (2015-2020)

2 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Competition by Company

1 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales and Market Share by Company (2015-2020)

2.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Revenue and Share by Company (2015-2020)

2.3 Global Hematopoietic Stem Cell Transplantation (HSCT) Price by Company (2015-2020)

2.4 Global Top Players Hematopoietic Stem Cell Transplantation (HSCT) Manufacturing Base Distribution, Sales Area, Product Types

2.5 Hematopoietic Stem Cell Transplantation (HSCT) Market Competitive Situation and Trends

2.5.1 Hematopoietic Stem Cell Transplantation (HSCT) Market Concentration Rate

2.5.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share of Top 5 and Top 10 Players

2.5.3 Mergers & Acquisitions, Expansion

3 Hematopoietic Stem Cell Transplantation (HSCT) Company Profiles and Sales Data

1 China Shipping Container Lines

3.1.1 Company Basic Information, Manufacturing Base and Competitors

3.1.2 Hematopoietic Stem Cell Transplantation (HSCT) Product Category, Application and Specification

3.1.3 China Shipping Container Lines Hematopoietic Stem Cell Transplantation (HSCT) Sales, Revenue, Price and Gross Margin(2015-2020)

3.1.4 Main Business Overview

4 Hematopoietic Stem Cell Transplantation (HSCT) Market Status and Outlook by Regions

1 Global Market Status and Outlook by Regions

4.1.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size and CAGR by Regions

4.1.2 North America

4.1.3 Asia-Pacific

4.1.4 Europe

4.1.5 South America

4.1.6 Middle East and Africa

4.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales and Revenue by Regions

4.2.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales and Market Share by Regions (2015-2020)

4.2.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Revenue and Market Share by Regions (2015-2020)

4.2.3 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales, Revenue, Price and Gross Margin (2015-2020)

4.3 North America Hematopoietic Stem Cell Transplantation (HSCT) Sales, Revenue, Price and Gross Margin

4.3.1 United States

4.3.2 Canada

4.3.3 Mexico

4.4 Europe Hematopoietic Stem Cell Transplantation (HSCT) Sales, Revenue, Price and Gross Margin

4.4.1 Germany

4.4.2 UK

4.4.3 France

4.4.4 Italy

4.4.5 Russia

4.4.6 Turkey

4.5 Asia-Pacific Hematopoietic Stem Cell Transplantation (HSCT) Sales, Revenue, Price and Gross Margin

4.5.1 China

4.5.2 Japan

4.5.3 Korea

4.5.4 Southeast Asia

4.5.4.1 Indonesia

4.5.4.2 Thailand

4.5.4.3 Malaysia

4.5.4.4 Philippines

4.5.4.5 Vietnam

4.5.5 India

4.5.6 Australia

4.6 South America Hematopoietic Stem Cell Transplantation (HSCT) Sales, Revenue, Price and Gross Margin

4.6.1 Brazil

4.7 Middle East and Africa Hematopoietic Stem Cell Transplantation (HSCT) Sales, Revenue, Price and Gross Margin

4.7.1 Egypt

4.7.2 GCC Countries

5 Hematopoietic Stem Cell Transplantation (HSCT) Application/End Users

1 Hematopoietic Stem Cell Transplantation (HSCT) Segment by Application

5.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Product Segment by Application

5.2.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales by Application

5.2.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales and Market Share by Application (2015-2020)

6 Global Hematopoietic Stem Cell Transplantation (HSCT) Market Forecast

1 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales, Revenue Forecast (2020-2026)

6.1.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales and Growth Rate Forecast (2020-2026)

6.1.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Revenue and Growth Rate Forecast (2020-2026)

6.2 Global Hematopoietic Stem Cell Transplantation (HSCT) Forecast by Regions

6.2.1 North America Hematopoietic Stem Cell Transplantation (HSCT) Sales and Revenue Forecast (2020-2026)

6.2.2 Europe Hematopoietic Stem Cell Transplantation (HSCT) Sales and Revenue Forecast (2020-2026)

6.2.3 Asia-Pacific Hematopoietic Stem Cell Transplantation (HSCT) Sales and Revenue Forecast (2020-2026)

6.2.3.1 China

6.2.3.2 Japan

6.2.3.3 Korea

6.2.3.4 Southeast Asia

6.2.3.5 India

6.2.3.6 Australia

6.2.4 South America Hematopoietic Stem Cell Transplantation (HSCT) Sales and Revenue Forecast (2020-2026)

6.2.5 Middle East and Africa Hematopoietic Stem Cell Transplantation (HSCT) Sales and Revenue Forecast (2020-2026)

6.2.5.1 Egypt

6.2.5.2 GCC Countries

6.3 Hematopoietic Stem Cell Transplantation (HSCT) Forecast by Type

6.3.1 Global Hematopoietic Stem Cell Transplantation (HSCT) Sales and Revenue Forecast by Type (2020-2026)

6.4 Hematopoietic Stem Cell Transplantation (HSCT) Forecast by Application

Read the original here:
Hematopoietic Stem Cell Transplantation (HSCT) Market: How Top Leading Companies Can Make This Smart Strategy Work - The Daily Chronicle

Bone Marrow Stem Cells Comments Off on Hematopoietic Stem Cell Transplantation (HSCT) Market: How Top Leading Companies Can Make This Smart Strategy Work – The Daily Chronicle | September 12th, 2020

If someone were to stop me in the street and ask me to give a limb to save a life, I wouldnt hesitate, says Rosenberg passionately. What good is a hand when it comes to an entire life?

By Mendel Super Chabad.org

Rabbi Yigal Rosenberga well-loved community rabbi in California and co-director ofChabad of Santa Clarawith his wife, Elanaisnt new to saving lives. From domestic violence to drug addiction, the rabbi doesnt shy away from involvement in lifesaving activities, but instead finds himself propelled towards them. But seldom does one get the opportunity to directly save a life in a very physical way.

In mid-February, before the emerging pandemic would dominate the headlines, as well as the lives of him and his community members, Rosenberg hosted a cooking demonstration at a local Lexus dealership featuring local gourmet chefTanyaSolomon, coupled with a bone marrow donor swabbing drive on behalf of the Gift of Life registryone of two private U.S. stem-cell registries.

Donor turnout was high, with virtually all attendees getting swabbed, a brief process in which a long cotton swab collects cells from the inside of the cheek, where they are then shipped off to a lab to determine their human leukocyte antigens, or HLA markers. Once the tissue type is determined, potential donors are added to a worldwide registry, which is made available to transplant centers and physicians.

Since only 30 percent of patients find a match within their immediate family, the majority need to search the registries. As bone marrow matches are very much dependent on the donor and recipient sharing specific genetic markers, the next best shot after family is ones ethnic group. While Gift of Life services the general community, many of their matches are betweenAshkenazicJews due to the relatively small size of their gene pool.

Days after the swabbing drive, Rosenberg received a call from Gift of Life officials. Assuming that they were calling about his recent donor drive, he was stunned when they told him he was a match. Your stem cells can save the life of a 40-year-old man with leukemia, they said. Taken aback, Rosenberg informed them that while he was happy to help, among all the hustle and bustle of the event he hadnt actually had a chance to join the registry and be swabbed. They told me I was on the registry from a drive at the Rabbinical College of America in Morristown, N.J., more than 10 years before! hetold Chabad.org.

The rabbi doesnt see this as mere coincidence. When we help others,Gdhelps us, he reflects. What greater opportunity can one have than to save the life of another? Its the embodiment of ourshlichusto help our fellow in every way possible.

If someone were to stop me in the street and ask me to give a limb to save a life, I wouldnt hesitate, says Rosenberg passionately. What good is a hand when it comes to an entire life? And giving bone marrow was far easier.

To give the life-giving serum, Rosenberg would have to drive to Los Angeles for several days to LifeStream Blood Bank in San Bernardino, a transplant center nearly eight hours away by car. Gift of Life arranged all the accommodation, but nobody could replace the rabbi at home. We have three children of our own, the rabbi explains, and now, because schools are closed for in-person learning, were accommodating local Jewish kids atChabadfor their virtual school. Fourteen children spend eight hours a day at theChabad center, keeping up with their general virtual studies in a safe environment. During breaks, they enjoy an array of in-person Jewish educational activities. We just had ashofarfactory and made thank you cards for the firefighters battling Californias wildfires, shares Rosenberg.

Before traveling to Los Angeles, the rabbi had to be conditioned for the transplant. He received several shots of Neupogen dailyeven onShabbat, after consulting a senior rabbito stimulate his bone marrow into producing extra stem cells.

At the transplant center in Los Angeles, Rosenberg was hooked up to a machine for eight hours, extracting the stem cells from his blood. All my blood left my body three times during the procedure, he says, noting that it was mostly painless.

The precious stem cells were immediately hand-delivered by special courier to the patient in N.J., whose identity is legally withheld from the donor for five years.

Rosenberg, who is also a chaplain with the Santa Clara police department, received well-wishes and support from many in the broader community, including the mayor, deputy mayor and various faith leaders he works with.

Left to hold down the fort in Santa Clara for three days, Elana Rosenberg was very supportive of her husbands decision. I felt grateful for the opportunity that my husband had to be able to help someone in a way that no one else could, she says, noting that out of 7 billion people in the world, only he was a match for that young man; Im just praying that the recipient of the donation takes it well and can continue to lead a life of purpose in good health.

(Reprinted with permission from Chabad.org)

View post:
Bone Marrow Donor Drive Saves a Life in an Unexpected Way - Anash.org - Good News

Bone Marrow Stem Cells Comments Off on Bone Marrow Donor Drive Saves a Life in an Unexpected Way – Anash.org – Good News | September 12th, 2020

In nearly 40 years of the HIV epidemic, only two people have likely been cured of the virus. Both scenarios resulted from stem cell transplants needed to fight blood cancers such as leukemia. Inspired by these two cases, a team of scientists is studying a multipronged way to potentially control HIV without medication. It involves two different genetic alterations of immune cells and with a safer method of stem cell transplants, also referred to as bone marrow transplants, a procedure that is generally toxic and dangerous.

The research is being funded by a five-year $14.6 million grant from the National Institutes of Health. The scientists coleading the preclinical studies are Paula Cannon, PhD, a distinguished professor of molecular microbiology and immunology at the Keck School of Medicine of the University of Southern California, and Hans-Peter Kiem, MD, PhD, who directs the stem cell and gene therapy program at the Fred Hutchinson Cancer Research Center, also known as Fred Hutch. According to a Keck School of Medicine press release, the two other main partners are David Scadden, MD, a bone marrow transplant specialist and professor at Harvard University and the Harvard Stem Cell Institute, and the biotechnology company Magenta Therapeutics.

In the HIV cure scenariosinvolving the so-called Berlin and London patientsboth men received stem cell transplants from donors with a natural genetic mutation that made them resistant to HIV. Specifically, their genes resulted in immune cells that lack CCR5 receptors on their surface (HIV latches onto these receptors to infect cells). Unfortunately, this method isnt viable for the nearly 38 million people worldwide living with HIV. Not only is it expensive, toxic and riskyit involves wiping out the patients immune system and replacing it with the new immune cellsbut it also requires matched donors who are CCR5 negative. According to the press release, about 1% of the population have this mutation.

With funding from this new grant, researchers hope to overcome these challenges in several ways. First, Cannon has already developed a gene-editing method to remove the CCR5 receptors from a patients own stem cells. She now hopes to further genetically engineer stem cells so they release antibodies that block HIV.

Our engineered cells will be good neighbors, Cannon said in the press release. They secrete these protective molecules so that other cells, even if they arent engineered to be CCR5 negative, have some chance of being protected.

Fred Hutchs Kiem will use CAR-T therapya new method of genetically modifying immune cells that is emerging out of cancer researchwith the goal of creating T cells that attack HIV-infected cells.

In addition, other scientists involved in the federal grant aim to develop less toxic methods of bone marrow transplantationfor example, by reducing the amount of chemotherapy required and speeding up the process of creating the new immune system.

The research finding could translate to other illnesses, such as cancer, sickle cell anemia and autoimmune disorders.

A home run would be that we completely cure people of HIV, Cannon said. What Id be fine with is the idea that somebody no longer needs to take anti-HIV drugs every day because their immune system is keeping the virus under control so that it no longer causes health problems and, importantly, they cant transmit it to anybody else.

For the latest on the cure cases, see Famed London Man Probably Cured of HIV from earlier this year. And in related news, see $14M Federal Grant to Research CAR-T Gene Therapy to Cure HIV.

More here:
$14.6M Grant to Explore a Therapy to Control HIV Without Meds - POZ

Bone Marrow Stem Cells Comments Off on $14.6M Grant to Explore a Therapy to Control HIV Without Meds – POZ | September 12th, 2020

DBMR has added a new report titled Global Stem Cell Banking Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. this report provides exact information about market trends, industrial changes, and consumer behaviour etc. The report assists in outlining brand awareness, market landscape, possible future issues, industry trends and customer behaviour about industry which eventually leads to advanced business strategies. Being a verified and reliable source of information, this market research report offers a telescopic view of the existing market trends, emerging products, situations and opportunities that drives the business in the right direction of success. The report has been framed with the proper use of tools like SWOT analysis and Porters Five Forces analysis methods.

Global stem cell banking market is set to witness a substantial CAGR of 11.03% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. The increased market growth can be identified by the increasing procedures of hematopoietic stem cell transplantation (HSCT), emerging technologies for stem cell processing, storage and preservation. Increasing birth rates, awareness of stem cell therapies and higher treatment done viva stem cell technology.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-banking-market&pm

Competitive Analysis:

Global stem cell banking market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of inflammatory disease drug delivery market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Few of the major competitors currently working in global inflammatory disease drug delivery market are: NSPERITE N.V, Caladrius, ViaCord, CBR Systems, Inc, SMART CELLS PLUS, LifeCell International, Global Cord Blood Corporation, Cryo-Cell International, Inc., StemCyte India Therapeutics Pvt. Ltd, Cordvida, ViaCord, Cryoviva India, Vita34 AG, CryoHoldco, PromoCell GmbH, Celgene Corporation, BIOTIME, Inc., BrainStorm Cell Therapeutics and others

Market Definition:Global Stem Cell Banking Market

Stem cells are cells which have self-renewing abilities and segregation into numerous cell lineages. Stem cells are found in all human beings from an early stage to the end stage. The stem cell banking process includes the storage of stem cells from different sources and they are being used for research and clinical purposes. The goal of stem cell banking is that if any persons tissue is badly damaged the stem cell therapy is the cure for that. Skin transplants, brain cell transplantations are some of the treatments which are cured by stem cell technique.

Cord Stem Cell Banking MarketDevelopment and Acquisitions in 2019

In September 2019, a notable acquisition was witnessed between CBR and Natera. This merger will develop the new chances of growth in the cord stem blood banking by empowering the Nateras Evercord branch for storing and preserving cord blood. The advancement will focus upon research and development of the therapeutic outcomes, biogenetics experiment, and their commercialization among the global pharma and health sector.

Cord Stem Cell Banking MarketScope

Cord Stem Cell Banking Marketis segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of the cord stem cell banking marketis further analyzed based on maximum granularity into further segmentation. On the basis of storage type, the market is segmented into private banking, public banking. On the basis of product type, the market is bifurcated into cord blood, cord blood & cord tissue. On the basis of services type, the market is segmented into collection & transportation, processing, analysis, storage. On the basis of source, market is bifurcated into umbilical cord blood, bone marrow, peripheral blood stem, menstrual blood. On the basis of indication, the market is fragmented into cerebral palsy, thalassemia, leukemia, diabetes, autism.

Cord stem cell trading is nothing but the banking of the vinculum plasma cell enclosed in the placenta and umbilical muscle of an infant. This ligament plasma comprises the stem blocks which can be employed in the forthcoming time to tackle illnesses such as autoimmune diseases, leukemia, inherited metabolic disorders, and thalassemia and many others.

Market Drivers

Increasing rate of diseases such as cancers, skin diseases and othersPublic awareness associated to the therapeutic prospective of stem cellsGrowing number of hematopoietic stem cell transplantations (HSCTs)Increasing birth rate worldwide

Market Restraint

High operating cost for the therapy is one reason which hinders the marketIntense competition among the stem cell companiesSometimes the changes are made from government such as legal regulations

Key Pointers Covered in the Cord Stem CellBanking MarketIndustry Trends and Forecast to 2026

Market SizeMarket New Sales VolumesMarket Replacement Sales VolumesMarket Installed BaseMarket By BrandsMarket Procedure VolumesMarket Product Price AnalysisMarket Healthcare OutcomesMarket Cost of Care AnalysisMarket Regulatory Framework and ChangesMarket Prices and Reimbursement AnalysisMarket Shares in Different RegionsRecent Developments for Market CompetitorsMarket Upcoming ApplicationsMarket Innovators Study

Key Developments in the Market:

In August, 2019, Bayer bought BlueRock for USD 600 million to become the leader in stem cell therapies. Bayer is paying USD 600 million for getting full control of cell therapy developer BlueRock Therapeutics, promising new medical area to revive its drug development pipeline and evolving engineered cell therapies in the fields of immunology, cardiology and neurology, using a registered induced pluripotent stem cell (iPSC) platform.In August 2018, LifeCell acquired Fetomed Laboratories, a provider of clinical diagnostics services. The acquisition is for enhancement in mother & baby diagnostic services that strongly complements stem cell banking business. This acquisition was funded by the internal accruals which is aimed to be the Indias largest mother & baby preventive healthcare organization.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-banking-market&pm

Research objectives

To perceive the most influencing pivoting and hindering forces in Cord Stem Cell Banking Market and its footprint in the international market.Learn about the market policies that are being endorsed by ruling respective organizations.To gain a perceptive survey of the market and have an extensive interpretation of the Cord Stem Cell Banking Market and its materialistic landscape.To understand the structure of Cord Stem Cell Banking Market by identifying its various sub segments.Focuses on the key global Cord Stem Cell Banking Market players, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Cord Stem Cell Banking Market submarkets, with respect to key regions (along with their respective key countries).To strategically profile the key players and comprehensively analyze their growth strategiesTo analyze the Cord Stem Cell Banking Market with respect to individual growth trends, future prospects, and their contribution to the total market.

Customization of the Report:

All segmentation provided above in this report is represented at country levelAll products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Read the original:
Global Stem Cell Banking Market Is Projected To Witness Vigorous Expansion By 2026 - Kewaskum Statesman News Journal

Bone Marrow Stem Cells Comments Off on Global Stem Cell Banking Market Is Projected To Witness Vigorous Expansion By 2026 – Kewaskum Statesman News Journal | September 12th, 2020

Stem Cells Market Report

The research study on the Global Stem Cells Market is a thorough investigation of the value and supply chain of the market and offers all-inclusive data about the industry. The report also covers insightful information about pricing, cost, value, capacity, gross revenue, and profit margins with reference to historical analysis and forecast estimation. The report also strives to identify demands and trends in different sectors of the Stem Cells market in major geographies of the world.

The Stem Cells market has witnessed dynamic changes in trends and demands owing to the ongoing COVID-19 pandemic. The report provides a detailed outlook on how the pandemic has affected the key segments of the Stem Cells industry. The report includes an in-depth impact analysis of the COVID-19 pandemic on the overall Stem Cells industry and covers a futuristic impact scenario.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2981

The report studies the market dynamics to identify and scrutinize the strategic initiatives and tactics undertaken by the industry players in order to gain a robust footing in the market and to achieve a substantial global position. It provides exhaustive analysis and imparts insightful data to help the readers understand the Stem Cells industry in detail and gain a competitive advantage over other players. The report also provides strategic recommendations to new and emerging players to help them formulate better entry and investment strategies.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Thermo Fisher Scientific, Agilent Technologies, Illumina, Inc., Qiagen, Oxford Nanopore Technologies, Eurofins Scientific, F. Hoffmann-La Roche, Danaher Corporation, Bio-Rad Laboratories, and GE Healthcare

The report offers a comprehensive analysis of the Stem Cells market inclusive of product portfolio, categories, applications, and a comprehensive analysis of the value chain structure. The study investigates several factors influencing the growth of the market and provides a competitive advantage to the readers.

The Stem Cells market report is an investigative study that provides insights into opportunities, limitations, and barriers encountered by the companies that influence or hinder the growth of the industry. Overall the report provides valuable information and an overview of the market scenario to gain a better understanding of the market.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2981

Product Outlook (Revenue, USD Billion; 2017-2027)

Technology Outlook (Revenue, USD Billion; 2017-2027)

Therapy Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

The report covers an extensive regional analysis and market estimation in each region and covers key geographical regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/stem-cells-market

Key Point Summary of the Report:

Thank you for reading our report. For further queries, please connect with us to know more about the report and its customization. Our team will ensure the report is customized accurately to meet your requirements.

Take a look at other reports from Reports and Data on PR Newswire:

Spine Biologics Market: Spine Biologics Market to Reach USD 2,629.6 Million By 2027 | CAGR: 3.9%

Isobutanol Market: Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4%

Hematology Analyzers and Reagents Market: Hematology Analyzers and Reagents Market to Reach USD 12.10 Billion By 2027

Isobutanol Market: Isobutanol Market to Reach USD 1555.8 Million By 2027 | CAGR: 6.4%

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Connect with us:Blogs|LinkedIn|Twitter

More:
Stem Cells Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application - News Degree

IPS Cell Therapy Comments Off on Stem Cells Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application – News Degree | September 12th, 2020

Induced pluripotent stem cells (iPSCs) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 2,442.97 million by 2027 growing at a CAGR of 7.5% in the above-mentioned forecast period. Increasing R&D investment activities is expected to create new opportunity for the market.

This induced pluripotent stem cells (iPSCs) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

To Remain Ahead Of Your Competitors, Request for a FREE Sample Here (with covid 19 Impact Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-induced-pluripotent-stem-cells-market&Dw

Increasing demand for personalized regenerative cell therapies among medical researchers & healthcare is expected to enhance the market growth. Some of the other factors such as increasing cases of chronic diseases, growing awareness among patient, rising funding by government & private sectors and rising number of clinical trials is expected to drive the induced pluripotent stem cells (iPSCs) market in the forecast period of 2020 to 2027.

Global Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size

Induced pluripotent stem cells (iPSCs) market is segmented of the basis of derived cell type, application and end- user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Make an Enquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-stem-cells-market&DW

The countries covered in the induced pluripotent stem cells (iPSCs) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The country section of the induced pluripotent stem cells (iPSCs) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

The major players covered in the induced pluripotent stem cells (iPSCs) market report are Thermo Fisher Scientific Inc., FUJIFILM Corporation, Horizon Discovery Ltd., Takara Bio Inc, Cell Applications, Inc., Lonza Group AG, Evotec A.G., ViaCyte, Inc., CELGENE CORPORATION, Fate Therapeutics, Astellas Pharma Inc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Read More @ https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-stem-cells-market?DW

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email @ Corporatesales@databridgemarketresearch.com

Read more:
Covid-19 Impact On Induced Pluripotent Stem Cells (iPSCs) Market 2020 Is Thriving Globally With Horizon Discovery Ltd., Takara Bio Inc, Cell...

Cardiac Stem Cells Comments Off on Covid-19 Impact On Induced Pluripotent Stem Cells (iPSCs) Market 2020 Is Thriving Globally With Horizon Discovery Ltd., Takara Bio Inc, Cell… | September 12th, 2020

Global Stem Cell Reconstructive Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal.However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide.Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologouso Bone Marrowo Adipose Tissueo Blood Syngeneic OtherGlobal Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem CellGlobal Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn OtherGlobal Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute OthersGlobal Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

Global Stem Cell Reconstructive Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/54688

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:Name: Vikas GodageOrganization: MAXIMIZE MARKET RESEARCH PVT. LTD.Email:sales@maximizemarketresearch.comWebsite:www.maximizemarketresearch.com

Visit link:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Kewaskum Statesman News Journal

Cardiac Stem Cells Comments Off on Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) – Kewaskum Statesman News Journal | September 12th, 2020

While the sports world has attempted to prevent infections of COVID-19 and reduce its spread, some have raised concerns over the potential long-term consequences for athletes who have already been infected.

The virus has hit a number of star athletes. In Japan alone, Shintaro Fujinami of the Hanshin Tigers, Hayato Sakamoto of the Yomiuri Giants and Gotoku Sakai of the J. Leagues Vissel Kobe are among those who have tested positive.

Australian Mitch Langerak, a goalkeeper for Nagoya Grampus, became one of the J. Leagues first positive cases in early June. Fortunately he was asymptomatic and subsequently returned to the pitch when the leagues top flight resumed its season on July 4.

For me, it was a bit of a shock it was a major shock, Langerak told the Japan Times last month. (But) I didnt feel anything. I didnt feel any different. But I guess Im part of the exceptions, not the rule. I was very lucky.

As soon as I got out I tested negative twice, so I was OK to leave the hospital I was straight into training and within two days I was feeling strong and feeling back into it.

But in actuality, Langeraks experience is common among athletes in Japan who have tested positive for COVID-19, leaving some local medical officials optimistic about a lower risk of long-term effects. Yet the potential threat of reduced respiratory or pulmonary function looms large for those whose careers rely on being able to physically compete at the highest level.

Kentaro Iwata, professor of infectious disease at Kobe University, believes that athletes do not have to worry about whether the virus could severely affect their athletic performances after recovery.

Its evident if you look at the data: Athletes have been infected around the world, but the virus has barely caused any impact (on their post-recovery performances), Iwata said. In most cases, regardless of the sport, symptoms are mild and athletes recover naturally and return to their competitions. From the medical standpoint, there isnt much to be afraid of as far as athlete infections are concerned.

Iwata even described the virus as nearly harmless for healthy, young people, which can be used to describe most professional-level athletes, too.

Because the disease presents symptoms when the virus reaches a persons respiratory tract, it poses a possible risk to an athletes performance if their lungs are damaged as a result.

Iwata did not exclude the possibility, but described it as unlikely and said most people would face few or no symptoms during their recovery.

Vissel Kobes Gotoku Sakai has been infected with it, said Iwata, who is a fan of the Kansai-based soccer team. But after he received medical treatment and recovered, hes been running around at his highest level possible, playing twice a week or so.

There arent almost any problems with cardiopulmonary functions thats how its viewed generally. Im not going to deny that (a problem) could happen, though.

Kentaro Iwata, professor of infectious disease at Kobe University, believes athletes shouldnt fear long-term effects after recovering from the virus. | KAZ NAGATSUKA

Haruo Nakayama, a neurosurgeon and an infectious disease specialist for Toho University, did not rule out the possibility that the virus could affect respiratory systems long-term, even though currently available evidence is not yet conclusive.

The effect of the virus on respiratory systems after patients no longer need to be hospitalized has not been scientifically examined, Nakayama said. But when we observe the pictures of those infected and the symptoms that they claim after they are discharged, some of them have claimed to be physically worn out for a while, or it gets harder for them to exert themselves more than usual.

Thats not just older people, but there are some in their 20s and 30s claiming the same things.

Nakayama explained that the coronavirus could cause fibrosis in the lungs, causing the organs to lose flexibility.

If the lungs lose their flexibility, it could affect the cardiopulmonary functions of athletes and I would say the chance of that happening is not zero, he said.

Underlying medical conditions such as Type-1 diabetes, heart failure and respiratory disease can exacerbate the symptoms of the virus. Referring to Hanshin pitcher Minoru Iwata and Vissels Sergi Samper, who both are diabetic, Kentaro Iwata stated that high-risk patients, including those undergoing dialysis or using immunosuppressants or cariostatic drugs could be at risk for more severe symptoms.

To that end, Iwata criticized the participation of swimmer Rikako Ikee, who is recovering from leukemia, in a July event marking one year before the postponed Olympics at the National Stadium.

She had leukemia and (hematopoietic stem cell transplantation) and must have had so many immunosuppressive drugs, which made her weaker to infectious diseases, not just to the coronavirus, Iwata said. Im very angry with the people that brought her out to say something like Lets hope to have a (successful) Olympics next year. I think thats cruel.

While Iwata draws a positive image of athletes post-infection performances, team medical staff working directly with athletes as well as overseas medical officials who have dealt with higher numbers of severe cases have stronger concerns over potential long-term implications.

Nobuhisa Yoshida, a sports science and performance director for the B. Leagues Sunrockers Shibuya, said that athletes with more severe symptoms, if hospitalized for two to three weeks and quarantined further upon release, could require more time to return to their peak condition after experiencing decreases in activity levels and cardiopulmonary functions.

And if (their time away from training) gets longer, it could cause a decline in the volume of muscle and muscle strength as well as slower reflexes, said Yoshida, who previously worked as an athletic performance assistant for the NBAs San Antonio Spurs.

The level of effects from the coronavirus could vary depending on athletes situations as well physical conditions can differ greatly depending on whether they are in or out of season.

If an athlete gets infected during the season, their fatigue level is higher, Yoshida said. So you (as a medical staffer) try to develop the athletes physical condition steadily. If you can check the degree of the athletes physical decline based on data, you can check their readiness and make sure to bring it to where he can finally play, then give him a green light.

Grampus goalkeeper Mitch Langerak (right) made a quick return to training after recovering from COVID-19 in June. | KYODO

Overseas, an increase in residual damage to coronavirus patients hearts and lungs have spurred studies on the viruss potential long-term consequences.

John Swartzberg, a clinical professor emeritus of infectious diseases and vaccinology at the University of California, Berkeley, told the schools news portal in July that the virus seems to accelerate a great deal of scarring in the lungs.

Swartzberg also said that COVID-19 can directly attack heart muscle cells, and that the cytokine storm an excessive release of molecules that trigger an inflammatory response by the body caused by the coronavirus can hurt the heart as well as the lungs. He stated that there is evidence both for and against long-term damage.

We dont know what the long-term effects of that may be, Swartzberg said. But it could be that we will have a population of people who survive COVID-19 only to go on and have chronic cardiac problems.

Swartzberg referred to the central nervous system and the kidneys as other organs that could potentially be damaged by the virus.

Myocarditis inflammation of the heart muscle has been linked to the coronavirus in reports in the United States and Europe.

Some athletes in the U.S. and Europe have reported persistent and residual symptoms, such as coughs, tachycardia and fatigue, many weeks to months after initial coronavirus infections.

These potential post-COVID-19 effects do not seem to have been discussed widely in Japan, where the focus has been on the number of infections and the death toll. In the U.S. and Europe, officials have debated the necessities of pathways for athletes to return to intensive practices and competitions, including heart and lung screenings.

Nakayama admitted that the lack of such discussion within the Japanese sports community was in part due to a lack of sufficient evidence.

But Nakayama who serves as the executive adviser of the B. Leagues anti-coronavirus team said that the group has internally discussed the potential damage athletes face, although it has not been able to specify them in the leagues guidelines.

He said that if two-thirds of an infected athletes lungs are damaged when they are hospitalized, it can easily be inferred that their performance post-recovery will be infected.

And whether the athletes performance would get back to normal after working on rehab and all that, half a year or nine months later? Thats something we are going to find out later, Nakayama said. We dont know yet.

Staff writer Dan Orlowitz contributed to this story.

Follow this link:
Could COVID-19 have long-term effect on athletes' health? - The Japan Times

Cardiac Stem Cells Comments Off on Could COVID-19 have long-term effect on athletes’ health? – The Japan Times | September 12th, 2020

The study of Cosmetic Skin Care market is a compilation of the market of Cosmetic Skin Care broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Cosmetic Skin Care industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Cosmetic Skin Care industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Cosmetic Skin Care Market report @ https://hongchunresearch.com/request-a-sample/77005

Key players in the global Cosmetic Skin Care market covered in Chapter 4:HenkelNatura & CoKaoLaboratories IPRADMary KayBeiersdorfEste Lauder CompaniesCotyColgate-PalmoliveUnileverP&GShiseidoChanelJohnson & JohnsonAmorepacificRevlonKoseAvonLVMHL BrandsLOreal

In Chapter 11 and 13.3, on the basis of types, the Cosmetic Skin Care market from 2015 to 2026 is primarily split into:Anti-Aging Cosmetic ProductsSkin Whitening Cosmetic ProductsSensitive Skin Care ProductsAnti-Acne ProductsDry Skin Care ProductsWarts Removal ProductsInfants Skin Care ProductsAnti-Scars Solution ProductsMole Removal ProductsMulti Utility Products

In Chapter 12 and 13.4, on the basis of applications, the Cosmetic Skin Care market from 2015 to 2026 covers:Stem Cells Protection Against UVFlakiness ReductionRehydrate the Skin SurfaceMinimize wrinklesIncrease the viscosity of Aqueous

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

For a global outreach, the Cosmetic Skin Care study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Cosmetic Skin Care Market Report with [emailprotected] https://hongchunresearch.com/report/cosmetic-skin-care-market-size-2020-77005

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Cosmetic Skin Care Market

Chapter Four: Players Profiles

Chapter Five: Global Cosmetic Skin Care Market Analysis by Regions

Chapter Six: North America Cosmetic Skin Care Market Analysis by Countries

Chapter Seven: Europe Cosmetic Skin Care Market Analysis by Countries

Chapter Eight: Asia-Pacific Cosmetic Skin Care Market Analysis by Countries

Chapter Nine: Middle East and Africa Cosmetic Skin Care Market Analysis by Countries

Chapter Ten: South America Cosmetic Skin Care Market Analysis by Countries

Chapter Eleven: Global Cosmetic Skin Care Market Segment by Types

Chapter Twelve: Global Cosmetic Skin Care Market Segment by Applications12.1 Global Cosmetic Skin Care Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Cosmetic Skin Care Sales and Market Share by Applications (2015-2020)12.1.2 Global Cosmetic Skin Care Revenue and Market Share by Applications (2015-2020)12.2 Stem Cells Protection Against UV Sales, Revenue and Growth Rate (2015-2020)12.3 Flakiness Reduction Sales, Revenue and Growth Rate (2015-2020)12.4 Rehydrate the Skin Surface Sales, Revenue and Growth Rate (2015-2020)12.5 Minimize wrinkles Sales, Revenue and Growth Rate (2015-2020)12.6 Increase the viscosity of Aqueous Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Cosmetic Skin Care Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/77005

List of tablesList of Tables and FiguresTable Global Cosmetic Skin Care Market Size Growth Rate by Type (2020-2026)Figure Global Cosmetic Skin Care Market Share by Type in 2019 & 2026Figure Anti-Aging Cosmetic Products FeaturesFigure Skin Whitening Cosmetic Products FeaturesFigure Sensitive Skin Care Products FeaturesFigure Anti-Acne Products FeaturesFigure Dry Skin Care Products FeaturesFigure Warts Removal Products FeaturesFigure Infants Skin Care Products FeaturesFigure Anti-Scars Solution Products FeaturesFigure Mole Removal Products FeaturesFigure Multi Utility Products FeaturesTable Global Cosmetic Skin Care Market Size Growth by Application (2020-2026)Figure Global Cosmetic Skin Care Market Share by Application in 2019 & 2026Figure Stem Cells Protection Against UV DescriptionFigure Flakiness Reduction DescriptionFigure Rehydrate the Skin Surface DescriptionFigure Minimize wrinkles DescriptionFigure Increase the viscosity of Aqueous DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Cosmetic Skin Care Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Cosmetic Skin Care Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Cosmetic Skin CareFigure Production Process of Cosmetic Skin CareFigure Manufacturing Cost Structure of Cosmetic Skin CareFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Henkel ProfileTable Henkel Production, Value, Price, Gross Margin 2015-2020Table Natura & Co ProfileTable Natura & Co Production, Value, Price, Gross Margin 2015-2020Table Kao ProfileTable Kao Production, Value, Price, Gross Margin 2015-2020Table Laboratories IPRAD ProfileTable Laboratories IPRAD Production, Value, Price, Gross Margin 2015-2020Table Mary Kay ProfileTable Mary Kay Production, Value, Price, Gross Margin 2015-2020Table Beiersdorf ProfileTable Beiersdorf Production, Value, Price, Gross Margin 2015-2020Table Este Lauder Companies ProfileTable Este Lauder Companies Production, Value, Price, Gross Margin 2015-2020Table Coty ProfileTable Coty Production, Value, Price, Gross Margin 2015-2020Table Colgate-Palmolive ProfileTable Colgate-Palmolive Production, Value, Price, Gross Margin 2015-2020Table Unilever ProfileTable Unilever Production, Value, Price, Gross Margin 2015-2020Table P&G ProfileTable P&G Production, Value, Price, Gross Margin 2015-2020Table Shiseido ProfileTable Shiseido Production, Value, Price, Gross Margin 2015-2020Table Chanel ProfileTable Chanel Production, Value, Price, Gross Margin 2015-2020Table Johnson & Johnson ProfileTable Johnson & Johnson Production, Value, Price, Gross Margin 2015-2020Table Amorepacific ProfileTable Amorepacific Production, Value, Price, Gross Margin 2015-2020Table Revlon ProfileTable Revlon Production, Value, Price, Gross Margin 2015-2020Table Kose ProfileTable Kose Production, Value, Price, Gross Margin 2015-2020Table Avon ProfileTable Avon Production, Value, Price, Gross Margin 2015-2020Table LVMH ProfileTable LVMH Production, Value, Price, Gross Margin 2015-2020Table L Brands ProfileTable L Brands Production, Value, Price, Gross Margin 2015-2020Table LOreal ProfileTable LOreal Production, Value, Price, Gross Margin 2015-2020Figure Global Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Global Cosmetic Skin Care Revenue ($) and Growth (2015-2020)Table Global Cosmetic Skin Care Sales by Regions (2015-2020)Table Global Cosmetic Skin Care Sales Market Share by Regions (2015-2020)Table Global Cosmetic Skin Care Revenue ($) by Regions (2015-2020)Table Global Cosmetic Skin Care Revenue Market Share by Regions (2015-2020)Table Global Cosmetic Skin Care Revenue Market Share by Regions in 2015Table Global Cosmetic Skin Care Revenue Market Share by Regions in 2019Figure North America Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Europe Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Asia-Pacific Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Middle East and Africa Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure South America Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure North America Cosmetic Skin Care Revenue ($) and Growth (2015-2020)Table North America Cosmetic Skin Care Sales by Countries (2015-2020)Table North America Cosmetic Skin Care Sales Market Share by Countries (2015-2020)Figure North America Cosmetic Skin Care Sales Market Share by Countries in 2015Figure North America Cosmetic Skin Care Sales Market Share by Countries in 2019Table North America Cosmetic Skin Care Revenue ($) by Countries (2015-2020)Table North America Cosmetic Skin Care Revenue Market Share by Countries (2015-2020)Figure North America Cosmetic Skin Care Revenue Market Share by Countries in 2015Figure North America Cosmetic Skin Care Revenue Market Share by Countries in 2019Figure United States Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Canada Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Mexico Cosmetic Skin Care Sales and Growth (2015-2020)Figure Europe Cosmetic Skin Care Revenue ($) Growth (2015-2020)Table Europe Cosmetic Skin Care Sales by Countries (2015-2020)Table Europe Cosmetic Skin Care Sales Market Share by Countries (2015-2020)Figure Europe Cosmetic Skin Care Sales Market Share by Countries in 2015Figure Europe Cosmetic Skin Care Sales Market Share by Countries in 2019Table Europe Cosmetic Skin Care Revenue ($) by Countries (2015-2020)Table Europe Cosmetic Skin Care Revenue Market Share by Countries (2015-2020)Figure Europe Cosmetic Skin Care Revenue Market Share by Countries in 2015Figure Europe Cosmetic Skin Care Revenue Market Share by Countries in 2019Figure Germany Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure UK Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure France Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Italy Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Spain Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Russia Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Asia-Pacific Cosmetic Skin Care Revenue ($) and Growth (2015-2020)Table Asia-Pacific Cosmetic Skin Care Sales by Countries (2015-2020)Table Asia-Pacific Cosmetic Skin Care Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Cosmetic Skin Care Sales Market Share by Countries in 2015Figure Asia-Pacific Cosmetic Skin Care Sales Market Share by Countries in 2019Table Asia-Pacific Cosmetic Skin Care Revenue ($) by Countries (2015-2020)Table Asia-Pacific Cosmetic Skin Care Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Cosmetic Skin Care Revenue Market Share by Countries in 2015Figure Asia-Pacific Cosmetic Skin Care Revenue Market Share by Countries in 2019Figure China Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Japan Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure South Korea Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Australia Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure India Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Southeast Asia Cosmetic Skin Care Sales and Growth Rate (2015-2020)Figure Middle East and Africa Cosmetic Skin Care Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

More:
Impact Of Covid-19 on Cosmetic Skin Care Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - Owned

Skin Stem Cells Comments Off on Impact Of Covid-19 on Cosmetic Skin Care Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 – Owned | September 12th, 2020

The global research antibodies market is anticipated to rise at a notable pace over the forecast period. Antibodies display exceptional physiological properties that make them sought-after for cell research.

Antibodies display other properties too. As they have the ability to attach to specific molecules, this enables specific molecules to be isolated for research. Hence, this makes for a key factor for continual research to examine the physiology and anatomy of antibodies.

The report serves to identify prevailing growth trends based on which projections made. The report constitutes most relevant data pertaining to comprehend the growth dynamics of research antibodies market. Geographical distribution of the research antibodies market and an analysis of the competitive structure are highlights of the report.

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=58524

Global Research Antibodies Witness Most Promising Rise in Demand

Currently, pharmaceutical and biopharmaceutical companies are undertaking extensive R&D activities to introduce novel products. These pursuits involve widespread use of antibodies because of their exceptional physiological properties. Therefore, research on antibodies receives a boost for their use in secondary cell research.

At present, stem cell research is finding keen interest of researchers and geneticists. Several studies support the efficacy of stem cell for blood cancers, blood and bone marrow diseases, immune disorders. Lately, stem cells from the umbilical cord and stem cells from the blood stream have been used to treat rare blood related diseases. Due to the dependency an antibodies for stem cell research, researchers are involved to isolate different antibodies molecules. This is aiding growth of research antibodies market.

Request for Analysis of COVID19 Impact on Research Antibodies

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=58524

The study offers an in-depth assessment of various customers journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touch points. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

Key Players of Research Antibodies Report:

Prominent players in the global research antibodies market include Abcam plc, Agilent Technologies, and Thermo Fisher Scientific Inc.

Buy Research Antibodies Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=58524&ltype=S

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Go here to see the original:
Research Antibodies Market: Report Analysis Global Market Revenue and Share by Manufacturers Boosting the Healthcare Industry Worldwide - Owned

Bone Marrow Stem Cells Comments Off on Research Antibodies Market: Report Analysis Global Market Revenue and Share by Manufacturers Boosting the Healthcare Industry Worldwide – Owned | September 11th, 2020

In nearly 40 years of the HIV epidemic, only two people have likely been cured of the virus. Both scenarios resulted from stem cell transplants needed to fight blood cancers such as leukemia. Inspired by these two cases, a team of scientists is studying a multipronged way to potentially control HIV without medication. It involves two different genetic alterations of immune cells and with a safer method of stem cell transplants, also referred to as bone marrow transplants, a procedure that is generally toxic and dangerous.

The research is being funded by a five-year $14.6 million grant from the National Institutes of Health. The scientists coleading the preclinical studies are Paula Cannon, PhD, a distinguished professor of molecular microbiology and immunology at the Keck School of Medicine of the University of Southern California, and Hans-Peter Kiem, MD, PhD, who directs the stem cell and gene therapy program at the Fred Hutchinson Cancer Research Center, also known as Fred Hutch. According to a Keck School of Medicine press release, the two other main partners are David Scadden, MD, a bone marrow transplant specialist and professor at Harvard University and the Harvard Stem Cell Institute, and the biotechnology company Magenta Therapeutics.

In the HIV cure scenariosinvolving the so-called Berlin and London patientsboth men received stem cell transplants from donors with a natural genetic mutation that made them resistant to HIV. Specifically, their genes resulted in immune cells that lack CCR5 receptors on their surface (HIV latches onto these receptors to infect cells). Unfortunately, this method isnt viable for the nearly 38 million people worldwide living with HIV. Not only is it expensive, toxic and riskyit involves wiping out the patients immune system and replacing it with the new immune cellsbut it also requires matched donors who are CCR5 negative. According to the press release, about 1% of the population have this mutation.

With funding from this new grant, researchers hope to overcome these challenges in several ways. First, Cannon has already developed a gene-editing method to remove the CCR5 receptors from a patients own stem cells. She now hopes to further genetically engineer stem cells so they release antibodies that block HIV.

Our engineered cells will be good neighbors, Cannon said in the press release. They secrete these protective molecules so that other cells, even if they arent engineered to be CCR5 negative, have some chance of being protected.

Fred Hutchs Kiem will use CAR-T therapya new method of genetically modifying immune cells that is emerging out of cancer researchwith the goal of creating T cells that attack HIV-infected cells.

In addition, other scientists involved in the federal grant aim to develop less toxic methods of bone marrow transplantationfor example, by reducing the amount of chemotherapy required and speeding up the process of creating the new immune system.

The research finding could translate to other illnesses, such as cancer, sickle cell anemia and autoimmune disorders.

A home run would be that we completely cure people of HIV, Cannon said. What Id be fine with is the idea that somebody no longer needs to take anti-HIV drugs every day because their immune system is keeping the virus under control so that it no longer causes health problems and, importantly, they cant transmit it to anybody else.

For the latest on the cure cases, see Famed London Man Probably Cured of HIV from earlier this year. And in related news, see $14M Federal Grant to Research CAR-T Gene Therapy to Cure HIV.

Follow this link:
$14.6M Grant to Explore a Therapy to Control HIV Without Meds - Cancer Health Treatment News

Bone Marrow Stem Cells Comments Off on $14.6M Grant to Explore a Therapy to Control HIV Without Meds – Cancer Health Treatment News | September 11th, 2020

Theglobal bone marrow aspirate concentrates marketwas valued around US$ 130.0 Mn in 2016 is anticipated to register a stable CAGR of over 5.0% during forecast period of 2017 to 2025, according to a new report published by Transparency Market Research (TMR)titled Bone Marrow Aspirate Concentrates Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20172025. Growth of the global bone marrow aspirate concentrates market is driven by increased prevalence of and incidences of orthopedic diseases, and sports injuries, along with high growth of the cosmetic surgery industry and increasing applications of the BMAC products in the cosmetic and orthopedic surgeries. The bone marrow aspirate concentrates market in Asia Pacific is expanding with a high potential to grow registering a CAGR above 6.0% on the backdrop of unmet clinical needs, rising geriatric population, large patient pool, favorable government regulations, development in health care sector, and increased focus on research and developmental activities.

Increase in incidences of Osteoarthritis on the backdrop of rising geriatric population to drive market growth

According to a collaborative survey conducted by the United Nations and the World Health Organization, 1.2 billion people in China are suffering from OA, of which more than 55% are aged 60 years or above. On the backdrop of such a huge patient base, there has been several developments in the field orthopedic surgery. Bone marrow-derived stem cell treatment is considered a promising and advanced therapy. It reduces the injury healing time in orthopedic diseases to five to six weeks from four to six months in case of surgery. Reduction in the healing time is a factor likely to propel theBone Marrow Aspirate Concentrates marketduring the forecast period. However, pain associated with the treatment, lack of product approval, and preference for alternative treatments are negatively affecting the market growth. Moreover, high investments in R&D and clinical trials, slow approval processes entailing sunken costs, and marginal returns on investment (RoI) for stakeholders are primary concerns faced by manufacturer further hampering growth of the market.

Get Brochure of the Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40451

Rise in the Number of BMAC Assisted Procedures to Boost Growth of Bone Marrow Aspirate Concentrates Accessories Segment

The product type segment is fragmented into bone marrow aspirate concentrates systems and bone marrow aspirate concentrates accessories. The bone marrow aspirate concentrates accessories segment is anticipated to carry major share of the market on the backdrop of rise in number of BMAC assisted procedures. Cell therapies have been used extensively over the past decade for a variety of medical applications to restore cellular function and enhance quality of life. Owing to the differentiation property, stem cells are being used for repair and regeneration of bone. Moreover, increase in awareness about hygiene and risk of cross-contamination in developing countries such as Brazil, China and India are expected to increase the use of single-use Jamshidi needles for bone marrow stem cell procedures. This is likely to fuel the growth of the accessories segment in the near future.

Orthopedic Surgery Application to Dominate the GlobalBone Marrow Aspirate Concentrates Market

The application segment of global bone marrow aspirate concentrates market is divided into orthopedic surgery, wound healing, chronic pain, peripheral vascular disease, dermatology, and others applications. Of which, orthopedic surgery segment is anticipated to dominate the market owing to rising geriatric population, and surge in incidences of osteoarthritis around the globe. The dermatology segment is anticipated to expand at the highest CAGR of over 6.0% during forecast period of 2017 to 2025 owing to current boom in the industry, increase in disposable income, and technological advancements in the market. The utilization of the regenerative ability of fibroblasts and keratinocytes from human skin has formed new ways to develop cell-based therapies for patients. Moreover, capacity of bone marrow derived extra-cutaneous cells is being researched for its plasticity in regenerating skin; it is likely to lead to the future growth of cell therapies in dermatology.

Rise in Healthcare Expenditure to Fuel Growth ofHospitals & Clinics End-user Segment

In terms of end-users, market is divided into hospitals & clinics, pharmaceutical & biotechnology companies, Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs), and academic & research institutes. The hospitals & clinics segment dominated the bone marrow aspirate concentrates market in 2016. The trend is expected to continue during the forecast period. The hospitals & clinics segment is likely to be followed by the biotechnology & biopharmaceutical companies segment in terms of market share during the forecast period. The segment is anticipated to hold more than 8.0% of market share in 2016. Growth of the segment is attributed to increasing number of biotechnology companies and rising partnerships among the market players to expand global presence.

Request For Covid19 Impact Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=40451

Large Patient Pool in Developing Countries Like China, India, Brazil, and Taiwan to Create More Opportunities in the Market

Geographically, global bone marrow aspirate concentrates market is divided into major five geographical regions, including North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. North America is anticipated to hold major share of the market owing to technological advancements and regulatory approval for new devices, awareness about stem cell therapy, and rise in number of cosmetic surgical procedures. While, Asia Pacific orthopedic market is at a pivotal point today, which was valued around US$ 19 Million in 2016 and anticipated to derive massive and augmented growth. The orthopedic market in Asia, including bone graft, spine, and bone substitute, is anticipated to grow more than twice as fast as the overall orthopedic market which will further boost growth of BMAC market in the region.

Semi-consolidated Market with 3-4 key Players Operating in the BMAC Systems Market Segment

Key players covered in this report are Terumo Corporation (Terumo BCT), Ranfac Corp., Arthrex, Inc., Globus Medical, Inc., Cesca Therapeutics Inc., MK Alliance Inc. (TotipotentSC), and Zimmer Biomet Holdings, Inc. Companies operating in the global market for bone marrow aspirate concentrates are focusing on in-licensing and collaboration agreements to put new products in the developing markets like Asia Pacific, and Latin America. For instance, in August 2017, Cesca Therapeutics Inc. announced a distribution agreement with Boyalife WSN Ltd., a China based company. Through this agreement, Boyalife WSN Ltd. will distribute Cescas innovative biobanking and point-of-care solutions in China, India, Singapore, and the Philippines. As India and China represent two of the fastest growing economies in the world, successful penetration of these regions can generate more market opportunity to the companies.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

The global bone marrow aspirate concentrates market is segmented as follows:

Global bone marrow aspirate concentrates market, by product

Global bone marrow aspirate concentrates market, by application

Global bone marrow aspirate concentrates market, by end-user

Global Bone Marrow Aspirate Concentrates Market, by Geography

More Trending Reports by Transparency Market Research 1.http://www.prnewswire.com/news-releases/increasing-number-of-accidents-and-injuries-to-drive-adoption-of-wound-closure-strips-market-valuation-to-rise-up-to-us446-3-mn-by-2027-end-finds-tmr-301019647.html

2.https://www.biospace.com/article/shoulder-replacement-market-growing-patients-for-reverse-shoulder-arthroplasty-add-sizable-revenues/

Read this article:
Bone Marrow Aspirate Concentrates Market Valuable Growth Prospects and Upcoming Trends Till 2025 - Science Examiner

Bone Marrow Stem Cells Comments Off on Bone Marrow Aspirate Concentrates Market Valuable Growth Prospects and Upcoming Trends Till 2025 – Science Examiner | September 11th, 2020

Bone marrowaspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) #https://www.trendsmarketresearch.com/report/sample/3184

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.

Get Complete TOC with Tables and[emailprotected]https://www.trendsmarketresearch.com/report/discount/3184

In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.

Get COVID-19 Report Analysis understand the COVID19 impact and be smart in redefining business strategies#https://www.trendsmarketresearch.com/report/covid-19-analysis/3184

Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others

Visit link:
Bone Marrow Processing System Market Insights Research Forecast By Upstream And Downstream Manufacturers Analysis 2018 2025 - Scientect

Bone Marrow Stem Cells Comments Off on Bone Marrow Processing System Market Insights Research Forecast By Upstream And Downstream Manufacturers Analysis 2018 2025 – Scientect | September 11th, 2020